# Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia

> **NCT03413462** · PHASE3 · COMPLETED · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 374 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** HS-25
- **DRUG:** Placebo of HS-25

## Key facts

- **NCT ID:** NCT03413462
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-12
- **Primary completion:** 2018-04-20
- **Final completion:** 2018-09-20
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03413462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03413462, "Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03413462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*